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ABSTRACT
The trailing endpoint phenotype observed during
testing of Candida albicans susceptibility to azoles
according to the CLSI procedure is deﬁned as a
difference in MIC depending on whether the
result is obtained after 24 or 48 h. This study
investigated whether intrinsic differences be-
tween the EUCAST and CLSI methods could
explain trailing growth. The glucose concentra-
tion in the medium and the shape of the micro-
titre plate wells were both found to be involved.
In order to reduce the incidence of trailing growth
according to the CLSI procedure, the use of higher
glucose concentrations and ﬂat-bottomed micro-
titre plates could be valuable improvements.
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Several standardised antifungal susceptibility
tests have been developed [1], including the CLSI
M27-A2 microdilution method [2] and the
EUCAST antifungal susceptibility testing method
for fermentative yeasts [3]. Despite differences
between these methods, they generally reveal
similar MICs [4]. However, the so-called ‘trailing
endpoint phenotype’ observed when using the
CLSI method can make the interpretation of MIC
values difﬁcult [5]. The trailing endpoint pheno-
type is deﬁned as a difference in MIC depending
on whether the result is obtained after incubation
for 24 or 48 h; after 24 h, the yeast appears to be
susceptible, but it appears to be resistant after
48 h [6]. The frequency of Candida albicans isolates
displaying trailing growth with ﬂuconazole can
be quite high (5–18%) [7,8], but fungal isolates
exhibiting a trailing endpoint phenotype appear
to remain susceptible in vivo [6,8]. The exact cause
of trailing growth has not been determined,
although it has been suggested that the pH of
the medium [9], the glucose concentration [10],
the inoculum size [10], the incubation tempera-
ture [11], and strain-dependent characteristics,
e.g., regulation of expression of resistance genes
[12], could be involved. Trailing is not observed
when using the EUCAST method, as reading after
48 h is not normally recommended. The present
study investigated whether other differences
between the two methods could explain the
trailing endpoint phenotype.
Non-trailing (NT) C. albicans isolate IHEM
9559 was obtained from the BCCM ⁄ IHEM Col-
lection (Brussels, Belgium), and trailing (T) isolate
98 ⁄ 472 was provided by M. Cuenca-Estrella
(National Centre forMicrobiology,Madrid, Spain).
Susceptibility testing to ﬂuconazole (Pﬁzer,
Brussels, Belgium) was performed according to
published guidelines [2,3], but the plates were
also read after 48 h when using the EUCAST
method. The medium used was RPMI-1640 with
L-glutamine and without sodium bicarbonate
(Life Technologies, Gent, Belgium), buffered to
pH 7.0 with 0.165 M morpholinepropanesul-
phonic acid. Doubling times were determined
spectrophotometrically. Optical densities were
measured using a Wallac Victor reader (Perkin
Elmer LAS, Waltham, MA, USA). For both meth-
ods, the MIC was considered to be the lowest
ﬂuconazole concentration that resulted in an
inhibition of growth of ‡50% of that of the
drug-free control.
According to the EUCAST procedure, the MIC
was the same for both isolates (0.25 mg ⁄L). In
contrast, according to the CLSI procedure, the
MIC was 0.25 mg ⁄L (at both time-points) for
the NT isolate, but increased after 48 h for the
T isolate (Fig. 1). Using the EUCAST procedure,
the shape of the well had no inﬂuence on the
turbidity and MIC value for both isolates, but
when using the CLSI method and the NT isolate,
ﬂat-bottomed wells resulted in a lower relative
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turbidity compared to round-bottomed wells,
although this had no effect on the MIC. With the
CLSI method and the T isolate, the relative
turbidity was higher in plates with round-bot-
tomed wells, and the relative turbidity after 48 h
had increased more in round-bottomed than in
ﬂat-bottomed wells, resulting in a shift in MIC
from 0.25 to >64 mg ⁄L (data not shown).
When the glucose concentration used in the
CLSI method was increased to 2% w ⁄ v after 24 h,
the increased concentration resulted in a higher
absolute turbidity at low ﬂuconazole concentra-
tions (<0.25 mg ⁄L) for both isolates, but no
difference in absolute turbidity was seen at high
concentrations. For the NT isolate, changes in
turbidity were minimal, and the same MIC was
observed with and without glucose. However, for
the T isolate, the addition of glucose resulted in a
more pronounced decrease in the relative turbid-
ity. Consequently, the MIC value in the presence
of glucose was the same as the MIC determined
after 24 h, while the MIC differed in the absence
of glucose, indicating that glucose is important for
the growth of C. albicans. To further investigate
this ﬁnding, doubling times were calculated for
both isolates in the presence and absence of
glucose. The T isolate had a shorter doubling
time (c. 140 min) than the NT isolate (c. 170 min),
and also had a shorter lag phase. While the
addition of glucose had no impact on the dou-
bling time of either isolate, low-glucose condi-
tions resulted in a shorter exponential phase for
the T isolate, which reached stationary phase
more rapidly (data not shown).
These results suggested that the use of wells
with ﬂat bottoms, as well as the addition of
glucose, might suppress the trailing phenotype.
Experiments were therefore performed, based on
the CLSI method, but using glucose 2% w ⁄ v and
round-bottomed wells. There was a marked
increase in turbidity following incubation for
24 h and 48 h for the T isolate (Fig. 2), but this
was less pronounced when using the standard
CLSI method (Fig. 1) and no trailing was obser-
Fig. 1. Effect of ﬂuconazole on the absolute turbidity obtained according to the EUCAST (left) and CLSI (right) methods
for trailing (T) and non-trailing (NT) isolates of Candida albicans. Note that reading the plate after 48 h is only recommended
in the CLSI procedure (data for 48 h obtained with the EUCAST procedure are shown for comparison only).
Fig. 2. Effect of ﬂuconazole on the absolute turbidity according to the CLSI method in the presence of glucose 2% w ⁄v
using round-bottomed wells (left) and ﬂat-bottomed wells (right) for trailing (T) and non-trailing (NT) isolates of Candida
albicans.
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ved. Using glucose 2% w ⁄ v and ﬂat-bottomed
wells, no difference in turbidity after incubation
for 24 h and 48 h was revealed (Fig. 2), which is
in agreement with the results obtained according
to the EUCAST method (Fig. 1).
The lower maximal absolute turbidity in the
growth control caused by a lower glucose con-
centration (and probably also by the 100-fold
lower inoculum), the fact that the maximal abso-
lute turbidity in the growth control was reached
earlier in faster-growing isolates, and the fact that
absolute turbidity in the ﬂuconazole-treated wells
increased more rapidly with faster-growing
isolates, can explain the trailing phenomenon
observed when using CLSI methodology. Trailing
will occur in situations where the maximal abso-
lute turbidity in the control wells has been
reached, while absolute turbidity is still increas-
ing in the ﬂuconazole-treated wells, which results
in a reduced difference between them. A trailing
endpoint will be obtained only if this situation
arises following incubation for between 24 h and
48 h, and if the difference in turbidity is sufﬁ-
ciently reduced. The odds of this situation occur-
ring are increased at low glucose concentrations,
because the growth control will reach a lower
maximal absolute turbidity more rapidly. In
addition, the odds of such a situation occurring
between 24 h and 48 h are higher for faster-
growing organisms. The results obtained in the
present study show that trailing depends on
isolate-speciﬁc characteristics, as well as certain
aspects of the method used. The higher glucose
concentration, as well as the use of ﬂat-bottomed
microtitre plates (as recommended in the
EUCAST procedure), seems to suppress the trail-
ing endpoint phenotype.
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